

Supplementary Table 4: IBD-related HCRU and costs in CD patients based on their first advanced therapy from 1L until censoring; pairwise comparison with IFX as reference after IPW adjustment

Health economic outcome parameters PPY	ADA (n=615) vs. IFX ¹	p-value ²	UST (n=620) vs. IFX ¹	p-value ²	VDZ (n=615) vs. IFX ¹	p-value ²
Number of IBD-related hospitalizations (events)	0.22 (0.45) vs. 0.29 (0.61)	0.013	0.27 (0.57) vs. 0.31 (0.63)	0.6	0.18 (0.31) vs. 0.32 (0.64)	0.002
Duration of IBD-related hospital stays (days)	2.85 (14.73) vs. 2.76 (8.91)	>0.9	2.0 (5.7) vs. 3.0 (9.3)	0.11	2.05 (5.20) vs. 2.99 (9.27)	0.2
Number of IBD-related surgeries (events)	0.29 (0.60) vs. 0.30 (0.70)	0.8	0.31 (0.93) vs. 0.31 (0.76)	>0.9	0.35 (0.73) vs. 0.31 (0.77)	0.7
Duration of IBD-related sick-leave (days)	21 (41) vs. 20 (38)	0.6	22 (48) vs. 20 (38)	0.8	27 (48) vs. 20 (38)	0.3
Number of IBD-related sick-leave (events)	0.78 (1.00) vs. 1.12 (1.54)	<0.001	0.85 (1.13) vs. 1.12 (1.53)	0.089	1.08 (1.33) vs. 1.11 (1.52)	0.9
Costs for IBD-specific hospitalizations (EUR)	1,375 (9,442) vs. 1,301 (3,651)	0.8	1,216 (2,819) vs. 1,407 (3,977)	0.5	1,360 (4,049) vs. 1,439 (4,053)	0.9
Costs for IBD-specific medication (EUR)	14,028 (8,239) (8,721) vs. 17,145 (10,181)	<0.001	30,391 (12,620) vs. 17,230 (10,253)	<0.001	16,637 (8,516) vs. 17,192 (10,252)	0.6
Costs for IBD-specific outpatient treatment (EUR)	655 (343) vs. 799 (413)	<0.001	726 (444) vs. 803 (420)	0.12	907 (463) vs. 810 (431)	0.044
Total costs for IBD-specific treatment (EUR)	16,192 (12,431) vs. 19,423 (10,408)	<0.001	32,590 (12,478) vs. 19,624 (10,500)	<0.001	19,182 (8,454) vs. 19,629 (10,527)	0.7
Total costs for all-cause treatment (EUR)	26,996 (39,912) vs. 29,208 (27,307)	0.2	53,043 (32,122) vs. 29,826 (28,351)	<0.001	37,202 (171,232) vs. 30,072 (28,531)	0.4

ADA= Adalimumab CD = Crohn's disease IBD = Inflammatory bowel disease IFX = Infliximab IPW = inverse probability weighting HCRU = Healthcare resource utilization PPY = Per Patient Year UST= Ustekinumab VDZ= Vedolizumab

¹Mean (SD), in ADA//VDZ/UST vs. IFX in CD patients

²Regression least-squares mean differences